Anesthetic management of patients with Brugada syndrome: a case series and literature review
- 7k Downloads
- 23 Citations
Abstract
Purpose
To review the anesthetic management and perioperative outcomes of patients diagnosed with Brugada syndrome (BrS) who were treated at a single centre and to compare those results with a comprehensive review of the existing literature.
Clinical features
A retrospective chart review of anesthesia records from patients diagnosed with BrS at the Mayo Clinic was undertaken with the emphasis on administered drugs, ST segment changes, and occurrence of complications, including death, hemodynamic instability, and dysrhythmias. Eight patients were identified who underwent a total of 17 operative procedures from 2000 through 2010. A total of 20 significant ST segment elevations were recorded in four patients, several of which occurred in close temporal relation to anesthetic drug administration. These elevations resolved uneventfully. There were no recorded dysrhythmias, and recovery from anesthesia proceeded uneventfully. A literature review of patients with BrS yielded 52 anesthetics in 43 patients. The only recorded complications included unmasking of a Brugada ECG pattern, one episode of polymorphic ventricular tachycardia, which converted spontaneously to sinus rhythm, and one episode of postoperative ventricular fibrillation in the setting of epidural anesthesia.
Conclusions
In this series and in the literature, BrS patients tolerated anesthesia without untoward disease-related complications. Propofol and local anesthetics carry a theoretical risk of arrhythmogenic potential in BrS patients, but clear evidence is lacking. However, awareness of their potential to induce arrhythmias warrants caution, especially with propofol infusions. Factors that might exacerbate ST segment elevations and subsequently lead to dysrhythmias (e.g., hyperthermia, bradycardia, and electrolyte imbalances, such as hyper- and hypokalemia and hypercalcemia) should be avoided or corrected.
Keywords
Etomidate Brugada Syndrome Right Bundle Branch Block Sodium Channel Blocker Intravenous LidocainePrise en charge de l’anesthésie chez les patients atteints d’un syndrome de Brugada: série de cas et analyse bibliographique
Résumé
Objectif
L’objectif de cette étude était de passer en revue la prise en charge de l’anesthésie et les pronostics périopératoires de patients atteints du syndrome de Brugada (BrS) traités dans un seul centre et de comparer ces pronostics à une analyse exhaustive de la littérature existante.
Éléments cliniques
Une révision rétrospective des dossiers anesthésiques de patients porteurs d’un BrS à la Clinique Mayo a été entreprise en recherchant particulièrement les médicaments administrés, les modifications au niveau du segment ST et la survenue de complications, y compris la mort, l’instabilité hémodynamique et les dysrythmies. Huit patients ont été identifiés. Au total, ils ont subi 17 opérations entre 2000 et 2010. Un total de 20 élévations significatives du segment ST a été enregistré chez quatre patients, dont plusieurs sont survenues à un moment proche de l’administration d’un anesthésique. Ces élévations se sont résolues sans incident. Aucune dysrythmie n’a été enregistrée, et la récupération après l’anesthésie s’est faite sans incident. Une analyse de la littérature portant sur des patients atteints de BrS a indiqué que 52 médicaments anesthésiques avaient été utilisés chez 43 patients. Les seules complications mentionnées sont la découverte d’un tracé typique du syndrome de Brugada à l’ECG, un épisode de tachycardie ventriculaire polymorphe, qui s’est spontanément transformée en rythme sinusal, et un épisode de fibrillation ventriculaire postopératoire dans le cadre d’une anesthésie péridurale.
Conclusion
Dans cette série et dans la littérature, les patients atteints de BrS ont toléré l’anesthésie sans complication fâcheuse liée à la maladie. Le propofol et les anesthésiques locaux comportent un risque théorique de potentiel arythmogène chez les patients atteints de BrS, mais nous ne disposons pas de données probantes claires. Toutefois, le fait d’être conscients de leur potentiel à induire des arythmies justifie que nous fassions preuve de prudence, particulièrement en ce qui touche aux perfusions de propofol. Les facteurs qui pourraient exacerber les élévations du segment ST et entraîner des dysrythmies (par ex., l’hyperthermie, la bradycardie et les déséquilibres électrolytiques tels que l’hyper- et l’hypokaliémie ainsi que l’hypercalcémie) doivent être évités ou corrigés.
Brugada syndrome (BrS) is a rare genetic autosomal dominant disease with incomplete penetrance which affects ion channels of the cardiac conduction system and causes a coved ST segment elevation in the right precordial leads with a pseudo right bundle branch block pattern. Patients afflicted with this disease can develop malignant ventricular arrhythmias. This disorder raises specific concerns as anesthesiologists routinely administer drugs that interact with cardiac ion channels which theoretically could trigger the development of malignant arrhythmias. Propofol infusions have induced Brugada-like electrocardiogram (ECG) abnormalities.1-6 The administration of sodium channel blockers to diagnose BrS by unmasking/provoking a type 1 Brugada ECG pattern raises safety concerns regarding the use of local anesthetics.7 As BrS is uncommon, with an estimated prevalence of approximately 1:5,000, large prospective studies to define the risks of anesthesia are impractical. We searched the Mayo Clinic medical records database to identify patients with BrS who underwent anesthesia and reviewed their anesthetic course. The purpose of this case series was to document perioperative adverse events in BrS patients within a single institution and to determine any possible association between adverse events in patients with BrS and anesthetic drugs administered in the perioperative setting.
Methods
After obtaining Institutional Review Board approval, a computerized search of the Mayo Clinic Rochester electronic medical records (EMR) database from 2000 through 2010 was conducted to identify patients with clinically diagnosed BrS who underwent anesthetic care. We performed a keyword search using the terms “SCN5A”, “Brugada”, “Sudden unexpected death syndrome”, and “SUDS” and refined our search by selecting terms to eliminate patients in whom BrS was excluded. Our inclusion criteria consisted of adult patients (aged ≥ 18 yr), procedures involving anesthesia care, and a clinical diagnosis of BrS. Since SCN5A-BrS accounts for only 20-30% of the disease, a positive genetic test result was not required for inclusion in the study. The only data included in the study were from patients who provided research authorization for the use of their medical records [Minnesota Statute 144.335 Subd. 3a. (d)].
The electronic medical and anesthesia records of eligible patients were reviewed by one of the authors (B.K.). Data were entered into a standardized data collection form, and all questionable entries were discussed with the senior authors. As BrS is a relatively heterogeneous disorder that imposes diagnostic challenges, the EMR of each subject was reviewed with a genetic cardiologist (M.J.A.) to obtain the most specific description of each patient’s BrS diagnosis. The following data were collected for each anesthetic: 1) drug usage (type, amount, time point) with specific focus on medications that conceivably could increase the risk of ventricular arrhythmias in a BrS host; 2) ST segment measurement (value, time point); and 3) pre-, peri-, and postprocedural events (specifically, arrhythmias, defibrillations, and episodes of hyperthermia defined by a core body temperature ≥ 38°C). ST segment changes were analyzed during time increments of two minutes. A change ≥ 1 mm in leads II and V5 measured at J+60 during two consecutive measurements (four-minute time period) was considered significant. ST segment depressions were excluded from the analysis due to lack of association with BrS. Since ST segment changes can be prone to artifacts, we correlated significant ST segment events with the drug administration time points. We observed that ST segment monitoring data were obtained from recordings of leads II and V5, neither of which assesses the right precordium, i.e., the area of the most typical ST segment changes in BrS patients. However, these were the two leads available from the electronic medical record. Intra- and postoperative hemodynamic variables were recorded. Abnormal values were defined as hypertension (systolic BP ≥ 30% of preinduction baseline), hypotension (systolic BP ≤ 30% of preinduction baseline), tachycardia (HR > 110 beats·min−1), and bradycardia (HR < 50 beats·min−1).
Principal findings
Brugada syndrome study patients
| Patient # | Sex | Age at first anesthetic exposure | Diagnosis |
|---|---|---|---|
| 1 | Male | 60 | Clinically diagnosed BrS with negative EP study |
| 2 | Female | 26 | Asymptomatic, type 1 BrS (i.e., SCN5A positive) |
| 3 | Male | 58 | Asymptomatic type 1 BrS |
| 4 | Male | 20 | Asymptomatic, genotype negative BrS |
| 5 | Male | 16 | Symptomatic type 1 BrS |
| 6 | Male | 35 | Clinically diagnosed BrS |
| 7 | Male | 48 | Clinically diagnosed BrS with positive EP study |
| 8 | Male | 41 | Asymptomatic type 1 BrS |
Demographic and clinical data of patients with Brugada syndrome undergoing anesthetic care
| Patient 1 | Patient 2 | Patient 2 | Patient 3 | Patient 4 | Patient 4 | Patient 4 | Patient 5 | Patient 5 | |
|---|---|---|---|---|---|---|---|---|---|
| Date of birth | 1947 | 1977 | 1977 | 1951 | 1983 | 1983 | 1983 | 1986 | 1986 |
| Surgical date (yr) | 2007 | 2003 | 2004 | 2009 | 2004 | 2008 | 2008 | 2003 | 2004 |
| Sex | Male | Female | Female | Male | Male | Male | Male | Male | Male |
| Age at procedure | 60 | 26 | 27 | 58 | 20 | 24 | 24 | 16 | 17 |
| ASA status | 3 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 3 |
| Procedure | Inguinal herniorrhaphy | Vaginal delivery | Tooth extraction | Sinus surgery | Dental extraction | Neurofibroma resection | Neurofibroma resection | ICD follow-up testing | ICD follow-up testing |
| Anesthesia technique | GA | Labour Epidural | MAC | GA | GA | GA | GA | MAC | MAC |
| Induction agent | Prop 150 mg | None | None | Sevo | Prop 250 mg | Prop 100 mg | Prop 100 mg Scopolamine | STP 100 mg | None |
| Induction adjuncts | Mid Lido 100 mg, Fent | None | None | Mid Fent | Lido 100 mg | Mid Fent | Mid Fent | Mid Fent, | None |
| Muscle relaxants | Suc Vec | None | None | Vec | Suc | None | None | None | None |
| Maintenance | Des N2O | Sufentanil 5 μg, 2-Chlorprocaine 1% 7 mL, Fentanyl-Bupivacaine 0.125% at 20 μg·hr−1 (total of 89 mg), Bupivacaine bolus (12.5 mg) | Mid Fent Propofol infusion | Iso N2O Remifentanil | Sevo N2O Prop 100 mg | Sevo N2O | Sevo N2O Prop 50 mg Prop infusion for 28 hr while intubated in ICU | Sevo N2O | Sevo N2O Fent Mid Prop 50 mg |
| Neuromuscular reversal | Neostigmine Glycopyrrolate | None | None | None | None | None | None | None | None |
| Vasoactive drugs | None | Ephedrine | None | Ephedrine | None | Ephedrine Phenylephrine | Phenylephrine Esmolol | None | None |
| Additional drugs | Ondansetron | None | Dexamethasone | Fentanyl Granisetron | Oxymetazoline Ondansetron | Hydromorphone Famotidine | Famotidine Dexamethasone | Ondansetron | Ondansetron |
| ECG changes | No | No | No | Yes | Yes | No | No | Yes | Yes |
| Intraoperative complications | Hypotension | Hypotension | None | Bradycardia | Hypotension, Tachycardia | Hypotension | Hypotension, Hypertension, Tachycardia | Hypotension, Tachycardia | Bradycardia |
| Postoperative complications | None | None | None | Hypertension | None | None | Hypotension, Tachycardia | None | Bradycardia |
| Surgical time | 78 min | N/A | 29 min | 236 min | 16 min | 53 min | 90 min | 61 min | 79 min |
| Postoperative level of care | PACU | Floor | PACU | PACU/ SICU | PACU | PACU | SICU | PACU | Floor |
| PACU time | 48 min | N/A | 25 min | 58 min (PACU) 1,116 min (ICU) | 33 min | 93 min | 2,817 min (ICU) | 75 min | 107 min |
| Patient 5 | Patient 5 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 8 | Patient 8 | |
|---|---|---|---|---|---|---|---|---|
| Date of birth | 1986 | 1986 | 1986 | 1970 | 1953 | 1967 | 1967 | 1967 |
| Surgical date (yr) | 2005 | 2006 | 2007 | 2005 | 2003 | 2008 | 2009 | 2010 |
| Sex | Male | Male | Male | Male | Male | Male | Male | Male |
| Age at procedure | 18 | 19 | 20 | 35 | 48 | 41 | 42 | 43 |
| ASA status | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 |
| Procedure | ICD follow-up testing | ICD follow-up testing | ICD follow-up testing | Thoracic laminectomy with cavernoma resection | Dental extraction | Prostate biopsy | Shoulder mass excision | Inguinal herniorrhaphy |
| Anesthesia technique | MAC | MAC | MAC | GA | MAC | MAC | MAC | GA |
| Induction agent | None | None | None | Prop 200 mg | None | None | None | Etomidate 30 mg |
| Induction adjuncts | None | None | None | Lido 80 mg, Fent Mid | None | None | None | Fent |
| Muscle Relaxants | None | None | None | Vec | None | None | None | Suc |
| Maintenance | Sevo Prop 100 mg | Sevo N2O STP 375 mg | Sevo STP 150 mg | Iso N2O | 2% Lidocaine 3.6 ml | Prop 60 mg Prop infusion 100 μg·kg−1·min−1 (total of 172.8 μg) | N2O Prop infusion 75 μg·kg−1·min−1 (total of 61.9 μg) | Des |
| Neuromuscular reversal | None | None | None | Neostigmine Glycopyrrolate | None | None | None | None |
| Vasoactive drugs | Ephedrine Phenylephrine | None | None | Labetalol | None | None | None | None |
| Additional drugs | None | None | Ondansetron Dexamethasone | Fent Famotidine Dexamethasone | None | None | Lido 40 mg Fent | Fent Ketorolac |
| ECG changes | No | Yes | No | No | No | No | Yes | Yes |
| Intraoperative complications | Hypotension, Bradycardia, Tachycardia | Hypotension, Bradycardia | Bradycardia, Tachycardia | Hypotension | None | None | None | None |
| Postoperative complications | Bradycardia | None | Bradycardia | Hypotension | None | None | None | Hypoxia, Hypoventilation |
| Surgical time | 16 min | 32 min | 15 min | 299 min | 13 min | 8 min | 19 min | 66 min |
| Postoperative level of care | PACU | PACU | PACU | PACU/ SICU | Floor | PACU | PACU | PACU |
| PACU time | 45 min | 51 min | 30 min | 50 min (PACU) 2,686 min (ICU) | N/A | 66 min | 78 min | 255 min |
Significant ST segment elevations with time-relation to perioperative application of drugs
| Patient # | Surgery # | Event # | ST change (mm) | Lead | Medication (application occurred number of minutes before ST segment change) |
|---|---|---|---|---|---|
| 3 | 1 | 1 | 1.3 | III | No medication given within preceding 25 minutes (granisetron and remifentanil) |
| 4 | 1 | 1 | 1.1 | V | oxymetazoline nasal (4 minutes) |
| 1 | 2 | 1.2 | II | oxymetazoline nasal (8 minutes), propofol (2 minutes), lidocaine (2 minutes), succinylcholine (2 minutes) | |
| 5 | 1 | 1, 2 | A total of 14 events occurred during three different surgeries which all involved monitored anesthesia care for ICD testing; due to the nature of ICD testing it is difficult to draw conclusions regarding the ST segment changes (influenced by movement and electrical stimulation). We therefore excluded the patient from this analysis. | ||
| 2 | 1-11 | ||||
| 4 | 1 | ||||
| 8 | 2 | 1 | 1.4 | V | propofol infusion (started 4 minutes), lidocaine (4 minutes), fentanyl (4 minutes) |
| 2 | 2 | 1.1 | V | propofol infusion (started 7 minutes), lidocaine (7 minutes), fentanyl (7 minutes) | |
| 3 | 1 | 1.2 | V | etomidate (0 minutes), dexamethasone (2 minutes), fentanyl (4 minutes, 2 minutes), heparin (2 minutes) |
Discussion
Our retrospective review of anesthetics performed in eight patients with diagnosed BrS showed that all patients tolerated anesthesia well. Some anesthetic agents (propofol, etomidate, lidocaine, succinylcholine, and nasal oxymetazoline) were noted to have a temporal association to ST segment elevations, a finding that is suspected to result in an increased risk of precipitating ventricular arrhythmias.
Brugada syndrome is an uncommon autosomal dominant genetic disease with incomplete penetrance and variable expressivity stemming from various mutations of ion channels in the cardiac conduction system.8,9 The disease is typically diagnosed during the fourth decade of life. Seven genotypes of BrS have been characterized, including mutations in cardiac sodium (types 1, 2, 5, and 7), potassium (type 6), and calcium (types 3 and 4) channels.8 Type 1 BrS, secondary to mutations in the SCN5A-encoded Nav1.5 sodium channel α-subunit, is the most common genetic subtype accounting for about 20-30% of BrS. The type 1 Brugada ECG pattern is the most specific ECG pattern for BrS. Type 1 is characterized by a coved-type ST segment elevation of at least 2 mm in the right precordial leads associated with a complete or incomplete right bundle branch block followed by a negative T wave.10 This ECG pattern can be either present at rest or inducible with sodium channel blockers, such as flecainide or procainamide. Patients may be asymptomatic, but they are at risk of developing ventricular tachycardia (VT) or fibrillation and sudden death.11,12 Type 2 Brugada ECG pattern presents with a saddleback appearance and either a positive or biphasic T wave. Type 3 Brugada ECG pattern can assume a saddleback or coved appearance, but it is characterized by less pronounced ST segment elevations. An observed type 1 ECG pattern is considered diagnostic when identified in conjunction with one of the following findings10,11 history of ventricular fibrillation or VT, family history of sudden cardiac death < 45 yr of age, coved-type ECGs in family members, inducibility of VT with programmed electrical stimulation, syncope or nocturnal agonal respiration. Type 2 and 3 ECG patterns are considered diagnostic when conversion to a type 1 ECG pattern is observed with the use of sodium channel blockers. Conversion of a type 3 ECG pattern to a type 2 ECG pattern is inconclusive.11
The pathophysiology behind the increased susceptibility to ventricular arrhythmias in BrS patients is beyond the scope of this article, but Morita et al. 9 present a comprehensive review. Physiologic stress,13 medications, and increased vagal activity14-16 can augment ST segment elevation. While a clear causal link between acute worsening of ST segment abnormalities and subsequent ventricular arrhythmias has not been established, multiple reports suggest such a relationship.17-20
It is difficult to formulate evidence-based guidelines for anesthetic management of these patients due to the absence of prospective studies combined with the low prevalence of BrS. Current guidelines are derived from theoretical models based on disease pathomechanism and observations from case reports and series.21 We conducted a literature search to compare our observations with previous reports regarding outcomes of patients with BrS who underwent anesthetic care. PubMed (1966-present) and EMBASE (1988-present) databases were searched using the following medical subject headings (MeSH): Brugada syndrome, anesthesia, anesthetics, and bupivacaine. Text words included: Brugada, anesthesia, anesthetics, anaesthesia, anaesthetics, bupivacaine, propofol, blockade, sympathomimetic, anticholinergic, perioperative, delivery, and caesarean. The search was limited to human subjects. In our search of anesthetic management of patients with BrS, we identified 21 case reports and four case series.
Articles in languages other than English were excluded,22-29 although an exception was made if an English abstract was provided that contained information about the surgical procedure and the medications used 30-33 or if the article was previously reviewed by another investigator (e.g., the case reports of Sugi et al. 34 and Lafuente et al.35 were reviewed in an article by Edge et al.).36
Previous reports of anesthesia in Brugada syndrome patients
| Age | Sex | Surgery | Drugs | Complications | Ref. |
|---|---|---|---|---|---|
| 7 | Male | Open inguinal hernia repair | Midazolam, sevoflurane, nitrous oxide, glycopyrrolate, fentanyl and wound infiltration with bupivacaine | None | |
| 3.5 | Male | Electrophysiologic study | Thiopental, vecuronium, fentanyl, sevoflurane, neostigmine | None | |
| 69 | Female | Colpohysterotomy | Atenolol, lorazepam, midazolam, fentanyl, propofol (induction bolus), TIVA (propofol, fentanyl), succinylcholine, atracurium, atropine, neostigmine, buprenorphine | None | |
| 60 | Male | AICD insertion | Diazepam, propofol, vecuronium, TIVA (propofol, fentanyl), atropine, ephedrine | Bradycardia, hypotension | |
| 51 | Male | AICD insertion | Diazepam, propofol, vecuronium, sevoflurane, nitrous oxide | None | |
| 56 | Male | AICD insertion | Diazepam, midazolam, vecuronium, sevoflurane, nitrous oxide, lidocaine, ephedrine | Hypotension | |
| 59 | Male | AICD insertion | Diazepam, propofol, vecuronium, TIVA (propofol, fentanyl), atropine | Bradycardia | |
| 63 | Male | AICD insertion | Diazepam, propofol, vecuronium, sevoflurane, nitrous oxide | None | |
| 63 | Male | AICD insertion | Diazepam, propofol, vecuronium, sevoflurane, nitrous oxide, lidocaine, diltiazem | None | |
| 55 | Male | Tooth extraction, incision and drainage of odontogenic infection | Lidocaine, propofol, succinylcholine, sevoflurane, nitrous oxide, lidocaine/ epinephrine (local infiltration), ephedrine | Hypotension | |
| 52 | Male | Laparotomy for small bowel obstruction | Thiopental, succinylcholine, fentanyl, isoflurane, nitrous oxide, vecuronium, glycopyrrolate, neostigmine, thoracic epidural catheter (0.25% bupivacaine, fentanyl) | None | |
| 33 | Male | Open patella fracture | Spinal anesthesia with 0.5% bupivacaine, PCA (opioids), NSAIDs | None | |
| 56 | Male | Spine fusion, L1 compression fracture | Thiopental, vecuronium, fentanyl, isoflurane, ketorolac, PCA (opioids) | None | |
| 26 | Male | Endoscopic sinus surgery | Midazolam, fentanyl, propofol, rocuronium, sevoflurane, nitrous oxide, neostigmine, glycopyrrolate | None | |
| 25 | Male | Appendectomy | Diazepam, propofol, fentanyl, cis-atracurium, sevoflurane, ketorolac | None | |
| 36 | Male | Varicocelectomy | Diazepam, propofol, fentanyl, cis-atracurium, sevoflurane, ketorolac | None | |
| 27 | Male | Appendectomy | Diazepam, propofol, fentanyl, cis-atracurium, sevoflurane, ketorolac | None | |
| 43 | Male | TURP | Diazepam, propofol, fentanyl, cis-atracurium, sevoflurane, ketorolac | None | |
| 51 | Male | Percutaneous nephrolithotripsy | Thiamylal, vecuronium, isoflurane, nitrous oxide, atropine, neostigmine | None | |
| 56 | Male | Plate fixation for mandibular fracture | Thiamylal, vecuronium, isoflurane, nitrous oxide, atropine, neostigmine | None | |
| 47 | Male | Hemilaminectomy | Propofol, fentanyl, droperidol, vecuronium, sevoflurane, neostigmine, atropine | ST segment elevation | |
| 49 | Male | Vocal cord polypectomy | Propofol, fentanyl, diazepam, mivacurium, glycopyrrolate, isoflurane, nitrous oxide | None | |
| 77 | Male | Gastrectomy for stomach cancer | Midazolam, propofol, fentanyl, rocuronium, sevoflurane, thoracic epidural catheter (0.125% bupivacaine, fentanyl) | Postoperative unmasking of Brugada-type ECG pattern by bupivacaine continuous infusion | |
| 68 | Male | Distal gastrectomy for stomach cancer | Propofol, fentanyl, vecuronium, sevoflurane, bilateral thoracic paravertebral block (0.5% ropivacaine), dopamine | Hypotension, polymorphic ventricular tachycardia | |
| N/A | N/A | Craniotomy, clipping of middle cerebral artery aneurysm | General anesthesia but no information about anesthetic drugs used except for low-dose dopamine and glycopyrrolate | Bradycardia | |
| 16 | Male | AICD insertion | Propofol, fentanyl, atracurium, sevoflurane, nitrous oxide, neostigmine, glycopyrrolate | Hypoxia, laryngospasm, pulmonary edema | |
| 40 | Female | Elective Cesarean delivery | Spinal anesthesia with 0.5% bupivacaine (13.5 mg) and diamorphine (400μg), phenylephrine, oxytocin | None | |
| 14 | Male | AICD insertion | Midazolam, TIVA (propofol, fentanyl), atracurium, neostigmine, glycopyrrolate | None | |
| 42 | Male | Comminuted calcaneus fracture repair | Spinal anesthesia with 0.5% levobupivacaine (13.5 mg), remifentanil | None | |
| 40 | Male | Radicular cyst excision | Midazolam, atropine, propofol, vecuronium, sevoflurane, nitrous oxide, fentanyl, lidocaine/ epinephrine (local infiltration) | None | |
| 70 | Male | Laryngeal cancer biopsy | Propofol, tramadol, sevoflurane, nitrous oxide | None | |
| 23 | Male | Tenotomy for lower extremity contracture | Sevoflurane, remifentanil | None | |
| N/A | N/A | AICD insertion | Thiopental, sevoflurane, nitrous oxide | None | |
| 38 | Male | Tibia/ fibula fracture, plate osteosynthesis | Propofol, remifentanil, cisatracurium, sevoflurane, morphine | None (some intra- and postoperative ST segment variations in V1-V3) | |
| 71 | Male | Lobectomy for lung cancer | Sevoflurane, epidural anesthesia (agent and dose were not reported) | PVCs, bradycardia, postoperative ventricular fibrillation |
Overall, our patients had unremarkable anesthetic courses. They exhibited normal responses to commonly used anesthetic agents, with the exception of two patients who experienced significant ST segment elevations in temporal relationship to administration of certain drugs, i.e., propofol, lidocaine, succinylcholine, oxymetazoline, or etomidate. All the documented ST segment elevations resolved spontaneously, and postanesthesia recovery times were not prolonged. The results support a small but consistent body of evidence describing relatively uneventful outcomes associated with general anesthesia and MAC sedation for patients with BrS.31-33,35-46 Despite the generally favourable outcomes, there remain several specific concerns that merit special consideration in patients with BrS.
Regional anesthesia and sodium-channel blockers
Regional anesthesia has been associated with complications in BrS. In a report by Fujiwara et al.,47 a patient with BrS developed polymorphic ventricular tachycardia 50 min following bilateral T8 paravertebral block using 40 mL of ropivacaine. However, concomitant use of a dopamine infusion to treat hypotension attributed to the block was a confounding factor which may have contributed to the development of the arrhythmia (see section “Vasoactive agents”). In a case reported by Phillips et al.,7 a previously asymptomatic patient developed Brugada-like ECG changes after a 14-hr infusion of bupivacaine in a thoracic epidural catheter. The bupivacaine infusion was discontinued and the ECG normalized over the ensuing 48 hr. The patient was given a provisional diagnosis of BrS based on the inducibility of a Brugada ECG pattern with sodium channel blockers, although no further evaluation was performed. Kaneda et al. 48 described a case in which a patient with diagnosed BrS developed ventricular fibrillation postoperatively after undergoing general and epidural anesthesia. Unfortunately, the article does not provide details regarding the medications used in the epidural (i.e., type of local anesthetic or dose). Interestingly, Kaneda et al.48 reported the successful use of intravenous lidocaine (intravenous bolus followed by continuous infusion) to control postoperative ventricular fibrillation in a BrS patient. In our series, one patient had a lumbar epidural placed for labour analgesia through which fentanyl-bupivacaine was applied by bolus and continuous infusion. No complications were noted.
Several authors reported uneventful regional or wound infiltration with local anesthetics in BrS patients.36-39,49 Local anesthetics are class Ib antiarrhythmics and thus block sodium channels. Intravenous lidocaine was reported to induce a Brugada ECG pattern which led to the diagnosis of BrS with subsequent identification of a V232I+L1308F double-missense mutation in the SCN5A gene.50 However, the effect of lidocaine may be dependent on specific ion channel mutation. For example, lidocaine exerted a beneficial effect in a patient with type 1 BrS secondary to a SCN5A-N406S missense mutation.51,52 Regardless, local anesthetics should be used cautiously, and if used, the dose should be minimized and the patient should be monitored closely. Four patients in our series received intravenous lidocaine without evidence of dysrhythmias, but an association with ST segment elevations was noted in three cases (Table 3).
Propofol and other induction agents
It has been suggested that propofol should be avoided in patients with BrS.21 Vernooy et al. 1 examined the relationship of ECG changes and sudden death in propofol infusion syndrome (PRIS). The group reported an index case in which PRIS induced a Brugada ECG pattern. A subsequent chart review revealed seven additional cases of PRIS; in six of those seven patients, a Brugada ECG pattern was recorded shortly before the occurrence of an electrical storm. Roberts et al. defined the features of PRIS in a large prospective incidence study published in 2009.53 The characteristics include development of metabolic acidosis and cardiac dysfunction along with at least one of rhabdomyolysis, hypertriglyceridemia, or renal failure after receiving intravenous propofol. In a report by Robinson et al.,4 an infant treated with continuous propofol infusion developed wide complex tachycardia with left bundle branch block morphology. This condition was cardioverted into a slower irregular rhythm with right bundle branch block morphology and pronounced ST segment elevations in V1. In a case reported by Riezzo et al.,3 a patient with long-term propofol abuse developed a Brugada ECG pattern with subsequent cardiovascular instability and death. The described presentation was reminiscent of PRIS with regard to cardiovascular instability and metabolic acidosis. An in vitro experiment on cardiac myocytes demonstrated that propofol exerts a dose-dependent blockade of whole cell sodium current and induces a hyperpolarizing shift in the voltage-dependence of the inactivation of sodium currents.54 Propofol has also been found to inhibit cardiac L-type calcium channels,55 attenuate beta-adrenergic signal transduction,56 and augment acetylcholine receptor activity.57
However, these adverse outcomes have occurred only in the setting of propofol abuse3 and PRIS.1,5,53 More importantly, none of the observed patients carried a diagnosis of BrS. Consequently, the only association between PRIS and BrS is the implication of propofol infusions in unmasking a Brugada ECG pattern.1-5 In a report by Weiner et al.,6 they described a Brugada ECG pattern induced by propofol infusion in a healthy young male who subsequently underwent testing and was found not to have BrS. Propofol has been used during anesthesia in BrS patients without incident.31,32,34,35,39-41,49 In our series, propofol was administered as a bolus in nine cases and as an infusion in three cases, and no dysrhythmias were observed. However, one patient who had received a propofol bolus and one patient who received a propofol infusion were noted to have significant ST segment elevations following propofol administration (within seven minutes after injection or start of infusion). The ST segments subsequently normalized spontaneously.
It is important to highlight that a type 1 Brugada ECG pattern is an electrocardiographic result which is not necessarily diagnostic of BrS in the absence of supporting findings. The differential diagnosis of a patient who exhibits a type 1 Brugada ECG pattern includes BrS, but it also encompasses various acquired diseases as well as cocaine58/marijuana59 use. In addition, multiple occurrences of drug-induced Brugada ECG patterns in previously healthy patients were reported,60-63 although those ECG changes were noted mostly in the setting of medication overdoses. Nevertheless, propofol has the potential to alter ion channel function. Despite theoretical concerns and various reports of adverse outcomes with propofol in a small subset of patients without known BrS, in our view, the clinical experience does not support the recommendation of avoiding bolus dosing for induction in BrS patients. Caution is advised for continuous infusions, however, as BrS patients may be more predisposed to cardiac arrhythmias due to their intrinsic ion channel malfunction.
Regarding other induction agents, thiopental use has been described in multiple case reports22,28,30,31 without problems, whereas no studies reported the use of etomidate. In our series, self-limited ST segment elevations were noted following etomidate administration, while no ST segment abnormalities were noted with the administration of thiopental.
Inhalational anesthetics, muscle relaxants, acetylcholine-esterase inhibitors, anticholinergics, and antiemetics
Inhalational anesthetics have not been associated with adverse events in BrS patients either in our series or in the literature.30-33,35-38,41-44,49 Both depolarizing and nondepolarizing neuromuscular blocking agents have been utilized clinically in our series and in previous case studies without incident.31,36,40,42-45 In our series as well as in the literature, nondepolarizing muscle relaxants were reversed with neostigmine without incident.36,40,42-45
Atropine31,40,43,49 and glycopyrrolate35,38,44,45 were used by other authors without problems. In our series, glycopyrrolate and scopolamine were used without adverse effects. Interestingly, in one study of patients with BrS, ST segment elevation was found in the right precordial leads after intracoronary acetylcholine (3/3 tested patients) and intravenous edrophonium administration (2/3 patients).20 In theory, given that increased vagal tone may increase arrhythmia susceptibility in a patient with BrS, the anticholinergic action of atropine, glycopyrrolate, and scopolamine drugs could exert a beneficial effect on ST segment changes. A variety of opioids has been used in our series and reported in the literature31-33,35-38,41,42,44,49 without adverse events in patients with BrS.
Commonly used antiemetics, including ondansetron, granisetron, and dexamethasone, have not been associated with any reported adverse effects in BrS patients, and all these drugs were used in our series without incident. Droperidol was not used in our patients, and it has been recommended to avoid phenothiazine antipsychotics (trifluoperazine, thioridazine, perphenazine).21 Phenothiazine overdoses have resulted in Brugada ECG patterns.64-66 Perphenazine has produced a reversible blockade of the Nav1.5 sodium current and the Kv4.3 transient outward potassium current (Ito) in isolated rat right ventricular cardiomyocytes,67 and trifluoperazine and chlorpromazine have reduced calcium inward current, sodium currents, and inwardly and delayed potassium currents in isolated guinea pig myocytes and bovine portal veins.68 However, the use of prochlorperazine has not been reported in BrS patients.
Vasoactive agents
Modulation of adrenergic receptors can modify ECG tracings in BrS patients by altering the ST segments.12 Alpha-receptor agonists20 and β-receptor antagonists69 can worsen ECG patterns by increasing the magnitude of ST segment elevation or unmasking a Brugada ECG pattern (change from normal ST segments to ST segment elevations), whereas α-receptor antagonists20 and β-receptor agonists20 improve ECG patterns by returning elevated ST segments back to baseline or decreasing the magnitude of ST segment elevations. The β1 and β2 receptor agonistic activity of isoproterenol increases calcium current and has been used to reduce ST segment elevation20 and suppress arrhythmic events in patients with BrS.70-73 Several approaches have been proven to successfully abrogate electrical storms. Joshi et al. 72 and Jongman et al.71 reported suppression of arrhythmias with an infusion of isoproterenol 1 μg·min−1. Watanabe et al.73 used a bolus/maintenance approach with isoproterenol with an initial bolus of 1-2 μg followed by a continuous infusion adjusted from 0.15-0.30 μg·min−1. Ohgo et al.70 showed an effect at lower doses of 0.002 μg·kg−1·min−1 with titration to 0.004 μg·kg−1·min−1. Besides the use of isoproterenol, the basic life support and advanced life support protocol should be no different for patients with BrS; however, data regarding the safety of other commonly used vasopressors are almost non-existent. Theoretically, the predominant β-agonist action of dobutamine could be beneficial, while other vasopressors with dual α- and β-agonist effect may have unpredictable effects. Epinephrine in conjunction with procainamide has been used to unmask Brugada,74 and norepinephrine can augment ST segment elevations. However, the use of dopamine75 and ephedrine49 has been described, and ephedrine was used in our series without complication. The selective α1-agonist activity of phenylephrine has theoretic potential to be deleterious, but it was used in our series without incident.
An overdose of the β-antagonist, propanolol, has been reported to unmask a Brugada ECG pattern.69 This change may have resulted from bradycardia and β-antagonism. However, propanolol at high doses binds to cardiac sodium channels inhibiting sodium uptake, and this action could have been the mechanism.63 In our series, one patient received esmolol and one patient received labetalol without incident.
Limitations
Precordial lead tracing (Patient 3). Typical right precordial lead tracings (V1-V3) showing T wave abnormalities typically observed in patients with Brugada syndrome
Another limitation of this retrospective case series is the small number of patients, which precluded a definitive proof of safety of any anesthetic agent or technique.
Conclusions
Patients with BrS in our series tolerated anesthesia without any untoward events other than episodes of spontaneously resolving ST segment elevation. However, with the exception of sodium channel blockers, clear data is clearly limited regarding the drugs that can exacerbate ST segment elevations and/or facilitate the development of ventricular arrhythmias in BrS patients. For a comprehensive review, we refer the reader to the current consensus statement published in 200921 or to the website, http://www.brugadadrugs.org. Our case series and a limited body of existing evidence report safe anesthetics using agents that theoretically are associated with possible problems when used in BrS patients, e.g. propofol (especially when given as a continuous infusion) and local anesthetics. In multiple studies, the β-agonist, isoproterenol, has been shown to be effective in normalizing ST segment elevations and in preventing electrical storm in BrS patients.
Notes
Financial Support
Support was provided solely from institutional and departmental sources (Department of Anesthesiology, Mayo Clinic, Rochester, MN).
Conflicts of interest
None declared.
References
- 1.Vernooy K, Delhaas T, Cremer OL, et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006; 3: 131-7.PubMedCrossRefGoogle Scholar
- 2.Junttila MJ, Gonzalez M, Lizotte E, et al. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation 2008; 117: 1890-3.PubMedCrossRefGoogle Scholar
- 3.Riezzo I, Centini F, Neri M, et al. Brugada-like EKG pattern and myocardial effects in a chronic propofol abuser. Clin Toxicol (Phila) 2009; 47: 358-63.CrossRefGoogle Scholar
- 4.Robinson JD, Melman Y, Walsh EP. Cardiac conduction disturbances and ventricular tachycardia after prolonged propofol infusion in an infant. Pacing Clin Electrophysiol 2008; 31: 1070-3.PubMedCrossRefGoogle Scholar
- 5.Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007; 62: 690-701.PubMedCrossRefGoogle Scholar
- 6.Weiner JB, Haddad EV, Raj SR. Recovery following propofol-associated Brugada electrocardiogram. Pacing Clin Electrophysiol 2010; 33: e39-42.PubMedCrossRefGoogle Scholar
- 7.Phillips N, Priestley M, Denniss AR, Uther JB. Brugada-type electrocardiographic pattern induced by epidural bupivacaine. Anesth Analg 2003; 97: 264-7.PubMedCrossRefGoogle Scholar
- 8.Hedley PL, Jorgensen P, Schlamowitz S, et al. The genetic basis of Brugada syndrome: a mutation update. Hum Mutat 2009; 30: 1256-66.PubMedCrossRefGoogle Scholar
- 9.Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm 2009; 6: S34-43.PubMedCrossRefGoogle Scholar
- 10.Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009; 24: 74-81.PubMedCrossRefGoogle Scholar
- 11.Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-70.PubMedCrossRefGoogle Scholar
- 12.Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006; 29: 1130-59.PubMedCrossRefGoogle Scholar
- 13.Amin AS, Klemens CA, Verkerk AO, et al. Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J 2010; 18: 165-9.PubMedCrossRefGoogle Scholar
- 14.Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999; 20: 465-70.PubMedCrossRefGoogle Scholar
- 15.Mizumaki K, Fujiki A, Nishida K, et al. Postprandial augmentation of bradycardia-dependent ST elevation in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18: 839-44.PubMedCrossRefGoogle Scholar
- 16.Mizumaki K, Fujiki A, Tsuneda T, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15: 667-73.PubMedCrossRefGoogle Scholar
- 17.Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95: 2277-85.PubMedGoogle Scholar
- 18.Noda T, Shimizu W, Taguchi A, et al. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40: 1841-7.PubMedCrossRefGoogle Scholar
- 19.Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998; 9: 508-12.PubMedCrossRefGoogle Scholar
- 20.Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-70.PubMedCrossRefGoogle Scholar
- 21.Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009; 6: 1335-41.
- 22.Carrera S, Sanchez JA, Abengochea JM, Cotera I. Ventricular fibrillation in a patient with a type I Brugada syndrome (Spanish). Rev Esp Anestesiol Reanim 2008; 55: 191-2.PubMedGoogle Scholar
- 23.De Gomez-Martinez ML, Fernandez-Garijo P, Rodriguez-Cabo F, et al. General anesthesia in patients presenting Brugads’s syndrome (Spanish). Rev Mex Anest 2008; 31: 311-4.Google Scholar
- 24.Hiuge Y, Ohta N, Hirata T, Mori T. Anesthetic management of two patients with Brugada-type ECG and of different clinical severity (Japanese). Masui 2004; 53: 693-5.PubMedGoogle Scholar
- 25.Imai Y, Niwa H, Yamada M, Harada J. Anesthetic management of a patient with Brugada syndrome. [Japanese]. J Jpn Dent Soc Anesthesiol 2005; 33: 277-8.Google Scholar
- 26.Ishigami T, Kishida T, Okushima K, Asano Y, Yokoyama K, Sugiyama K. Systemic management of a patient with Brugada syndrome. [Japanese]. J Jpn Dent Soc Anesthesiol 2004; 32: 632-3.Google Scholar
- 27.Kawaguchi Y, Kushikata T, Hashiba E, et al. Anesthetic management for patients with Brugada syndrome (Japanese). Masui 2006; 55: 142-9.PubMedGoogle Scholar
- 28.Lopez-Jimenez FA, Mondragon-Villanueva ME. Brugada syndrome and anesthesia (Spanish). Rev Mex Anest 2008; 31: 55-62.Google Scholar
- 29.Sato Y, Hirai Y, Tachinami Y, Yamaguchi T, Iwatsuki N. Anesthetic management of a patient with Brugada type ECG (Japanese). J Jpn Dent Soc Anesthesiol 2005; 33: 275-6.Google Scholar
- 30.Jindai R, Tanaki N, Ohmura S, Yamamoto K, Kobayashi T. Anesthetic management of a patient with Brugada syndrome for implantable cardioverter defibrillator implantation. (Japanese). Hokuriku J Anesthesiol 2000; 34: 21-4.Google Scholar
- 31.Kobayashi K, Shimosaka M, Uda A, et al. General anesthesia for a patient with Brugada-pattern ECG: an evaluation of heart rate variability using power spectrum (Japanese). J Jpn Dent Soc Anesthesiol 2003; 31: 32-8.Google Scholar
- 32.Ohmori A, Sugimoto K, Fujii K, et al. General anesthesia by use of tramadol in a Brugada syndrome patient with an implantable cardioverer defibrillator (Japanese). Anesthesia Resusc 2006; 42: 7-9.Google Scholar
- 33.Shinoda M, Hino H, Takabayashi R, Doi A, Yazaki T, Tateda T. Anesthesia for a patient with hypertrophic cardiomyopathy with Brugada syndrome (Japanese). Anesthesia Resusc 2010; 46: 65-8.Google Scholar
- 34.Sugi Y, Mori M, Ono M, Kurihara Y. Anesthetic management of a patient with Brugada syndrome (Japanese). Masui 2000; 49: 884-6.PubMedGoogle Scholar
- 35.Lafuente Martin FJ, Pascual Bellosta A, Abengochea Beisty JM, Fraca Cardiel C, Sanchez Tirado JA, Urieta Solanas JA. Brugada syndrome and anesthesia. Apropos of a case (Spanish). Rev Esp Anestesiol Reanim 1998; 45: 301-2.PubMedGoogle Scholar
- 36.Edge CJ, Blackman DJ, Gupta K, Sainsbury M. General anaesthesia in a patient with Brugada syndrome. Br J Anaesth 2002; 89: 788-91.PubMedGoogle Scholar
- 37.Kim JS, Park SY, Min SK, et al. Anaesthesia in patients with Brugada syndrome. Acta Anaesthesiol Scand 2004; 48: 1058-61.PubMedCrossRefGoogle Scholar
- 38.Baty L, Hollister J, Tobias JD. Perioperative management of a 7-year-old child with Brugada syndrome. J Intensive Care Med 2008; 23: 210-4.PubMedCrossRefGoogle Scholar
- 39.Theodotou N, Cillo JE Jr. Brugada syndrome (sudden unexpected death syndrome): perioperative and anesthetic management in oral and maxillofacial surgery. J Oral Maxillofac Surg 2009; 67: 2021-5.PubMedCrossRefGoogle Scholar
- 40.Vaccarella A, Vitale P, Presti CA. General anaesthesia in a patient affected by Brugada syndrome. Minerva Anestesiol 2008; 74: 149-52.PubMedGoogle Scholar
- 41.Santambrogio LG, Mencherini S, Fuardo M, Caramella F, Braschi A. The surgical patient with Brugada syndrome: a four-case clinical experience. Anesth Analg 2005; 100: 1263-6.PubMedCrossRefGoogle Scholar
- 42.Canbay O, Erden IA, Celebi N, Aycan IO, Karagoz AH, Aypar U. Anesthetic management of a patient with Brugada syndrome. Pediatr Anesth 2007; 17: 1225-7.CrossRefGoogle Scholar
- 43.Hayashida H, Miyauchi Y. Anaesthetic management in patients with high-risk Brugada syndrome. Br J Anaesth 2006; 97: 118-9.PubMedCrossRefGoogle Scholar
- 44.Candiotti KA, Mehta V. Perioperative approach to a patient with Brugada syndrome. J Clin Anesth 2004; 16: 529-32.PubMedCrossRefGoogle Scholar
- 45.Goraksha S, Bidaye S, Gajendragadkar S, Bapat J, Butani M. General anaesthesia for insertion of an automated implantable cardioverter defibrillator in a child with Brugada and autism. Indian J Anaesth 2010; 54: 562-4.PubMedCrossRefGoogle Scholar
- 46.Alves SET, Bezerra MJ. Spinal anaesthesia in Brugada syndrome: a case report. Annu Eur Soc Reg Anaesth 2010; 35: E61-2.Google Scholar
- 47.Fujiwara Y, Shibata Y, Kurokawa S, Satou Y, Komatsu T. Ventricular tachycardia in a patient with Brugada syndrome during general anesthesia combined with thoracic paravertebral block. Anesth Analg 2006; 102: 1590-1.PubMedCrossRefGoogle Scholar
- 48.Kaneda Y, Fujita N, Ueda K, et al. Surgically treated primary lung cancer associated with Brugada syndrome: report of a case. Surg Today 2001; 31: 817-9.PubMedCrossRefGoogle Scholar
- 49.Inamura M, Okamoto H, Kuroiwa M, Hoka S. General anesthesia for patients with Brugada syndrome. A report of six cases. Can J Anesth 2005; 52: 409-12.PubMedCrossRefGoogle Scholar
- 50.Barajas-Martinez HM, Hu D, Cordeiro JM, et al. Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res 2008; 103: 396-404.PubMedCrossRefGoogle Scholar
- 51.Clancy CE, Wehrens XH. Mutation-specific effects of lidocaine in Brugada syndrome. Int J Cardiol 2007; 121: 249-52.PubMedCrossRefGoogle Scholar
- 52.Itoh H, Tsuji K, Sakaguchi T, et al. A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome. Int J Cardiol 2007; 121: 239-48.PubMedCrossRefGoogle Scholar
- 53.Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13: R169.PubMedCrossRefGoogle Scholar
- 54.Saint DA. The effects of propofol on macroscopic and single channel sodium currents in rat ventricular myocytes. Br J Pharmacol 1998; 124: 655-62.PubMedCrossRefGoogle Scholar
- 55.Zhou W, Fontenot HJ, Liu S, Kennedy RH. Modulation of cardiac calcium channels by propofol. Anesthesiology 1997; 86: 670-5.PubMedCrossRefGoogle Scholar
- 56.Kurokawa H, Murray PA, Damron DS. Propofol attenuates beta-adrenoreceptor-mediated signal transduction via a protein kinase C-dependent pathway in cardiomyocytes. Anesthesiology 2002; 96: 688-98.PubMedCrossRefGoogle Scholar
- 57.Yamamoto S, Kawana S, Miyamoto A, Ohshika H, Namiki A. Propofol-induced depression of cultured rat ventricular myocytes is related to the M2-acetylcholine receptor-NO-cGMP signaling pathway. Anesthesiology 1999; 91: 1712-9.PubMedCrossRefGoogle Scholar
- 58.Liu M, Gaconnet G, London B, Dudley SC. Central role for mitochondria in regulation of sodium current. Neurourol Urodyn 2009; 28: 1690.CrossRefGoogle Scholar
- 59.Daccarett M, Freih M, Machado C. Acute cannabis intoxication mimicking Brugada-like ST segment abnormalities. Int J Cardiol 2007; 119: 235-6.PubMedCrossRefGoogle Scholar
- 60.Levine M, LoVecchio F. Diphenhydramine-induced Brugada pattern. Resuscitation 2010; 81: 503-4.PubMedCrossRefGoogle Scholar
- 61.Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK. Brugada-like electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol 2010; 33: 265-7.PubMedCrossRefGoogle Scholar
- 62.Palaniswamy C, Selvaraj DR, Chugh T, et al. Brugada electrocardiographic pattern induced by amitriptyline overdose. Am J Ther 2010; 17: 529-32.PubMedCrossRefGoogle Scholar
- 63.Rennyson SL, Littmann L. Brugada-pattern electrocardiogram in propranolol intoxication. Am J Emerg Med 2010; 28: 256.e7-8.CrossRefGoogle Scholar
- 64.Bolognesi R, Tsialtas D, Vasini P, Conti M, Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997; 79: 242-5.PubMedCrossRefGoogle Scholar
- 65.Copetti R, Proclemer A, Pillinini PP. Brugada-like ECG abnormalities during thioridazine overdose. Br J Clin Pharmacol 2005; 59: 608.PubMedCrossRefGoogle Scholar
- 66.Rouleau F, Asfar P, Boulet S, et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12: 61-5.PubMedCrossRefGoogle Scholar
- 67.Bebarova M, Matejovic P, Pasek M, et al. Effect of antipsychotic drug perphenazine on fast sodium current and transient outward potassium current in rat ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 125-33.PubMedCrossRefGoogle Scholar
- 68.Klockner U, Isenberg G. Calmodulin antagonists depress calcium and potassium currents in ventricular and vascular myocytes. Am J Physiol 1987; 253: H1601-11.PubMedGoogle Scholar
- 69.Aouate P, Clerc J, Viard P, Seoud J. Propranolol intoxication revealing a Brugada syndrome. J Cardiovasc Electrophysiol 2005; 16: 348-51.PubMedCrossRefGoogle Scholar
- 70.Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007; 4: 695-700.PubMedCrossRefGoogle Scholar
- 71.Jongman JK, Jepkes-Bruin N, Ramdat Misier AR, et al. Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally. Neth Heart J 2007; 15: 151-5.PubMedCrossRefGoogle Scholar
- 72.Joshi S, Raiszadeh F, Pierce W, Steinberg JS. Antiarrhythmic induced electrical storm in Brugada syndrome: a case report. Ann Noninvasive Electrocardiol 2007; 12: 274-8.PubMedCrossRefGoogle Scholar
- 73.Watanabe A, Fukushima Kusano K, Morita H, et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J 2006; 27: 1579-83.PubMedCrossRefGoogle Scholar
- 74.Krahn AD, Gollob M, Yee R, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation 2005; 112: 2228-34.PubMedCrossRefGoogle Scholar
- 75.Bethune W, Nozari A. Cerebral aneurysm surgery in a patient with Brugada syndrome: anesthetic implications and perioperative management. J Neurosurg Anesthesiol 2010; 22: 82-3.PubMedCrossRefGoogle Scholar
- 76.Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol 2000; 11: 95-8.PubMedCrossRefGoogle Scholar
- 77.Horigome H, Shigeta O, Kuga K, et al. Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta. J Electrocardiol 2003; 36: 339-43.PubMedCrossRefGoogle Scholar
- 78.Cordery R, Lambiase P, Lowe M, Ashley E. Brugada syndrome and anesthetic management. J Cardiothorac Vasc Anesth 2006; 20: 407-13.PubMedCrossRefGoogle Scholar
- 79.Bramall J, Combeer A, Springett J, Wendler R. Caesarean section for twin pregnancy in a parturient with Brugada syndrome. Int J Obstet Anesth 2011; 20: 181-4.PubMedCrossRefGoogle Scholar
- 80.Brunetti ND, De Gennaro L, Pellegrino PL, et al. Intra day ECG variation after general anesthesia in Brugada syndrome. J Interv Card Electrophysiol 2008; 21: 219-22.PubMedCrossRefGoogle Scholar